Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin

Zoltan Dekan, Thomas Kremsmayr, Peter Keov, Mathilde Godin, Ngari Teakle, Leopold Dürrauer, Huang Xiang, Dalia Gharib, Christian Bergmayr, Roland Hellinger, Marina Gay, Marta Vilaseca, Dennis Kurzbach, Fernando Albericio, Paul F. Alewood, Christian W. Gruber, Markus Muttenthaler

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Vasopressin (VP) and oxytocin (OT) are cyclic neuropeptides that regulate fundamental physiological functionsviafour G protein-coupled receptors, V1aR, V1bR, V2R, and OTR. Ligand development remains challenging for these receptors due to complex structure-activity relationships. Here, we investigated dimerization as a strategy for developing ligands with novel pharmacology. We regioselectively synthesised and systematically studied parallel, antiparallel and N- to C-terminal cyclized homo- and heterodimer constructs of VP, OT and dVDAVP (1-deamino-4-valine-8-d-arginine-VP). All disulfide-linked dimers, except for the head-to-tail cyclized constructs, retained nanomolar potency despite the structural implications of dimerization. Our results support a single chain interaction for receptor activation. Dimer orientation had little impact on activity, except for the dVDAVP homodimers, where an antagonist to agonist switch was observed at the V1aR. This study provides novel insights into the structural requirements of VP/OT receptor activation and spotlights dimerization as a strategy to modulate pharmacology, a concept also frequently observed in nature.

Original languageEnglish
Pages (from-to)4057-4062
Number of pages6
JournalChemical Science
Volume12
Issue number11
DOIs
Publication statusPublished - 21 Nov 2021
Externally publishedYes

Cite this